Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Free Cash Flow (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Free Cash Flow for 13 consecutive years, with $578000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 93.21% to $578000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $13.2 million, a 10.6% increase, with the full-year FY2025 number at $13.2 million, up 10.6% from a year prior.
  • Free Cash Flow was $578000.0 for Q4 2025 at Niagen Bioscience, down from $3.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $8.5 million in Q4 2024 to a low of -$8.2 million in Q2 2021.
  • A 5-year average of -$393850.0 and a median of $312000.0 in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 1886.35% in 2021, then soared 2997.64% in 2025.
  • Niagen Bioscience's Free Cash Flow stood at -$4.9 million in 2021, then soared by 89.89% to -$500000.0 in 2022, then skyrocketed by 225.6% to $628000.0 in 2023, then surged by 1255.73% to $8.5 million in 2024, then crashed by 93.21% to $578000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Free Cash Flow are $578000.0 (Q4 2025), $3.7 million (Q3 2025), and $1.1 million (Q2 2025).